Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for DexCom (DXCM) is 9/10.
DexCom posted 15% revenue growth with strong global new patient records and net income of $216.3 million ($0.56 per share, up 75%), as the G7 15-Day drove momentum with nearly 50% base conversion expected. Revenue guidance was reiterated at $5.16-5.20 billion while operating margin guidance was raised to 23-23.5% on strong cost discipline. International growth surged 26% with widespread gains and a Prime Therapeutics coverage win expanded Type 2 non-insulin share.
Scored from DexCom’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.11B | +7.6% | $0.38 | -38.7% | 58.9% | 17.0% | 13.6% | $177M |
| FY2025 Q1 | $1.04B | +12.5% | $0.27 | -25.0% | 56.9% | 12.9% | 10.2% | $97M |
| FY2025 Q2 | $1.16B | +15.2% | $0.45 | +28.6% | 59.5% | 18.4% | 15.5% | $209M |
| FY2025 Q3 | $1.21B | +21.6% | $0.70 | +105.9% | 61.8% | 20.1% | 23.5% | $579M |
| FY2025 Q4 | $1.26B | +13.1% | $0.68 | +78.9% | 62.9% | 25.6% | 21.2% | $192M |
| FY2026 Q1 | $1.19B | +15.0% | $0.51 | +88.9% | 62.9% | 21.4% | 16.7% | $449M |
| FY2026 Q2 | $1.31B | +13.1% | $0.64 | +42.2% | 63.4% | 24.3% | 19.0% | $185M |